DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 020603/S-021

SUPPLEMENT APPROVAL

Johnson & Johnson Consumer Inc.
McNeil Consumer Healthcare Division
Attention: Doris Roberts
Manager, Regulatory Affairs
7050 Camp Hill Road
Mail Stop 111
Fort Washington, PA 19034

Dear Ms. Roberts:

Please refer to your Supplemental New Drug Application (sNDA) dated and received February 29, 2016, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Infants' Motrin® (ibuprofen) suspension drops, 50 mg/1.25 mL.

This "Prior Approval" sNDA proposes the following changes:

1. Modifies the "Do Not Use" Warnings Section on carton and immediate containers
2. Changes corporate name on carton and immediate containers
3. Includes California-mandated slack fill requirements on principal display panel
4. Revises to metric only units of measure on carton and immediate containers

We have completed our review of this application. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

LABELING

Submit final printed labeling (FPL), as soon as they are available, but no more than 30 days after they are printed. The FPL must be identical to the submitted labeling (immediate container and carton labels listed below submitted February 29, 2016, and must be in the "Drug Facts" format (21 CFR 201.66), where applicable.

Submitted Labeling	Submission Date	Represented Labeling
0.5 oz berry carton (outer container)	02/29/2016	N/A
1 oz dye-free berry carton (immediate container)	02/29/2016	N/A
0.5 oz berry bottle (outer container)	02/29/2016	N/A
1 oz dye-free berry bottle (immediate container)	02/29/2016	N/A

The FPL should be submitted electronically according to the guidance for industry titled "Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008)." Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission "**Final Printed Labeling for approved NDA 020603/S-021**." Approval of this submission by FDA is not required before the labeling is used.

DRUG REGISTRATION AND LISTING

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf. In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Tinya Sensie, Regulatory Project Manager, at (240) 402-4230.

Sincerely,

{See appended electronic signature page}

Theresa Michele, MD
Director
Division of Nonprescription Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

ENCLOSURE:
Carton and Container Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

THERESA M MICHELE
08/29/2016